Maxim Group Reaffirms Their Hold Rating on Adial Pharmaceuticals (ADIL)

In a report released yesterday, Jason McCarthy from Maxim Group maintained a Hold rating on Adial Pharmaceuticals (ADILResearch Report). The company’s shares opened today at $0.29.

McCarthy covers the Healthcare sector, focusing on stocks such as Immutep, Daré Bioscience, and Adial Pharmaceuticals. According to TipRanks, McCarthy has an average return of -38.1% and a 14.47% success rate on recommended stocks.

The analyst consensus on Adial Pharmaceuticals is currently a Hold rating.

See the top stocks recommended by analysts >>

The company has a one-year high of $3.52 and a one-year low of $0.24. Currently, Adial Pharmaceuticals has an average volume of 166K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Adial Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which is focused on the treatment of alcohol use disorder. Its lead product AD04, a selective serotonin-3 antagonist is in Phase 3 clinical trial. The company was founded by Bankole A. Johnson in November 2010 and is headquartered in Charlottesville, VA.

Read More on ADIL:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More